中文
Earlier issues
Announcement
More
Progress in Chemistry 2008, Vol. 20 Issue (12): 2068-2074 Previous Articles   Next Articles

• Review •

Hypoxia Inducible Factor-1α :A New Anticancer Drug Target

Liu Yonghui1,2 Li Yuyan1 You Qidong1** Ding Lei2

  

  1. (1.Department of Pharmacy, China Pharmaceutical University, Nanjing 210009, China; 2. Jiangsu Simcere Pharmaceutical Research Institute, Nanjing 210042, China)

  • Received: Revised: Online: Published:
  • Contact: You Qidong
PDF ( 1561 ) Cited
Export

EndNote

Ris

BibTeX

Hypoxia is an important characteristic of neoplasma and some other diseases. For this reason, it is becoming an attractive research area to inhibit tumor growth by utilizing the hypoxia environment. The discovery of hypoxia inducible factor-1(HIF-1) has led to a rapidly increasing understanding of the molecular mechanism of tumor hypoxia in the past 15 years. Now it is generally accepted that HIF-1 perform a central role for tumor cells to regulate their metabolisms under hypoxia. Many genes are regulated by HIF-1，their expression will affect oxygen transportation, glucose uptake, glucolysis, and angiogenesis. Therefore, down regulation of the HIF system may interfere tumor’s adaption to hypoxia, thus making it an attractive target for cancer therapy. As most regulations occur on the HIF-1α subunit, researches focus on targeting HIF-1α, which lead to the discovery of a variety of small molecular HIF-1αinhibitors including camptothecin analogues, quinoxaline analogues, rapamycin analogues, some steroids, (aryloxyacetylamino) benzoic acid analogues and some naturally occurring substances like resveratrol and hesperidin. Here we summarize recent information on HIF-1α, especially HIF-1αinhibitors that have the potential of clinical usage.
Key words: hypoxia inducible factor-1α, cancer, inhibitors

CLC Number: 

[1 ] Brahimi-Horn M C , Pouyssegur J . FEBS Lett . , 2007 , 581 (19) :3582 —3591
[2 ] Semenza G L , Wang G L. Mol . Cell . Biol . , 1992 , 12 : 5447 —5454
[3 ] Semenza G L. Science , 2007 , 318 : 62 —64
[4 ] Harris A L. Nat . Rev. Cancer , 2002 , 2 : 38 —47
[5 ] Brahimi-Horn C , Pouyssegur J . Crit . Rev. Oncol . Hematol . ,2005 , 53 : 115 —123
[6 ] Jiang B H , Semenza GL , Bauer C , et al . Am. J . Physiol . Cell Physiol . , 1996 , 271 : Cl172 —Cl180
[7 ] Kiriakidis S , Esteban M A , Maxwell P H. Advan. Enzyme.Regul . , 2007 , 47 : 288 —306
[8 ] Lando D , Peet D J , Gorman J J , et al . Genes Dev. , 2002 , 16 :1466 —1471
[9 ] Lando D , Peet D J , Whelan D A , et al . Science , 2002 , 295 :858 —861
[10] Semenza G L. J . Appl . Physiol . , 2004 , 96 : 1173 —1177
[11] Chandel N S , Simon M C. Cell Death Differ. , 2008 , 15 : 619 —620
[12] 雷三林(Lei S L ) . 中南大学博士学位论文( Doctoral Dissertation of the Central South University) , 2006
[13] Lee K, Roth R A , LaPres J J . Pharmacol . Ther. , 2007 , 113 :229 —246
[14] Zhong H , DeMarzo A M, Laughner E , et al . Cancer Res. , 1999 ,59 : 5830 —5835
[15] Hirota K, Semenza G L. Crit . Rev. Oncol . Hematol . , 2006 ,59 : 15 —26
[16] Rankin E B , Giaccia A J . Cell Death Differ. , 2008 , 15 : 678 —685
[17] 范健(Fan J ) , 张华林(Zhang H L) , 谭春燕(Tan C Y) 等. 化学进展(Progress in Chemistry) , 2007 , 19 (12) : 1955 —1964
[18] Greijer A E , van der Wall E. J . Clin. Pathol . , 2004 , 57 (10) :1009 —1014
[19] Chang H , Shyu K G, Lee C C , et al . Biochem. Biophys. Res.Commun. , 2003 , 302 : 95 —100
[20] Shin D H , Kim J H , Jung YJ , et al . Cancer Lett . , 2007 , 255 :107 —116
[21] Park J W, Chun Y S , Kim M S , et al . J . Pharmacol . Sci . ,2004 , 94 : 221 —232
[22] Pili R , Donehower R C. J . Natl . Cancer Inst . 2003 , 95 (7) :498 —499
[23] Welsh S , Williams R , Kirkpatrick L , et al . Mol . Cancer Ther. ,2004 , 3 (3) : 233 —244
[24] Tan C , de Noronha R G, Roecker A J , et al . Cancer Res. ,2005 , 65 (2) : 605 —612
[25] Kong D , Park E J , Stephen A G, et al . Cancer Res. , 2005 , 65(19) : 9047 —9055
[26] Kung A L , Zabludoff S D , France D S. Cancer Cell , 2004 , 6 :33 —43
[27] Brugarolas J . N. Engl . J . Med. 2007 , 356 (2) : 185 —187
[28] Ishikawa A , Yoshida H , Metoki N , et al . Neurosci . Res. , 2007 ,59 : 406 —412
[29] Duyndam M C , Berkel M P , Dorsman J C , et al . Biochem.Pharmacol . 2007 , 74 : 191 —201
[30] Fukuda R , Kelly B , Semenza GL , et al . Cancer Res. , 2003 ,63 : 2330 —2334
[31] Semenza G L. Drug Discov. Today , 2007 , 12 : 853 —859
[32] Yao E J , Ryu J H , Cho Y S , et al . Blood , 2006 , 107 : 916 —923
[33] Rapisarda A , Uranchimeg B , Scudiero , D A , et al . Cancer Res. , 2002 , 62 : 4316 —4324
[34] Rapisarda A , Uranchimeg B , Sordet O , et al . Cancer Res. ,2004 , 64 : 1475 —1482
[35] Kamiyama H , Takano S , Tsuboi K, et al . J . Cancer Res. Clin.Oncol . , 2005 , 131 : 205 —213
[36] Torregrossa J , Bubley G J , Jones G B. Bioorg. Med. Chem.Lett . , 2006 , 16 : 6082 —6085
[37] Nagasawa H , Uto Y, Kirk K L , et al . , Biol . Pharm. Bull . ,2006 , 29 : 2335 —2342
[38] Weng Q J , Wang D D , Guo P , et al . , Eur. J . Pharmacol . ,2008 , 581 : 262 —269
[39] Hudson C C , Liu M, Chiang G G, et al . Mol . Cell . Biol . ,2002 , 22 : 7004 —7014
[40] Thomas G V , Tran C , Mellinghoff I K, et al . Nat . Med. , 2006 ,12 (1) : 122 —127
[41] Ito D , Fujimoto K, Mori T, et al . Inter. J . Cancer , 2006 , 118 :2337 —2343
[42] Teachey D T, Obzut D A , Cooperman J , et al . Blood , 2006 ,107 : 1149 —1155
[43] Vlaminck B , Toffoli S , Ghislain B , et al . FEBS Journal , 2007 ,274 (21) : 5533 —5542
[44] Mabjeesh N J , Post D E , Willard M T, et al . Cancer Res. ,2002 , 62 (9) : 2478 —2482
[45] Murgo A J , Kummar S , Gardner E R , et al . J . Clin. Onco.ASCO Annual Meeting Proceedings (Post-Meeting Edition) , 2007 ,25 (18S) : 3566
[46] Cheng H , Cao X H , Xian M, et al . J . Med. Chem. 2005 , 48(2) : 645 —652
[47] Brazidec J L , Kamal A , Busch D , et al . J . Med. Chem. , 2004 ,47 (15) : 3865 —3873
[48] Tian Z Q , Liu Y Q , Zhang D , et al . Bioorg. Med. Chem. ,2004 , 12 : 5317 —5329
[49] Ibrahim N O , Hahn T, Franke C , et al . Cancer Res. , 2005 , 65(23) : 11094 —11100
[50] Fotsis T, Zhang Y, Pepper M S , et al . Nature , 1994 , 368 :237 —239
[51] Schumacher G, Neuhaus P. J . Cancer Res. Clin. Oncol . , 2001 ,127 : 405 —410
[52] Ricker J L , Chen Z, Yang X P , et al . Clin. Cancer Res. , 2004 ,10 : 8665 —8673
[53] Mabjeesh N J , Escuin D , LaVallee T M, et al . Cancer Cell ,2003 , 3 : 363 —375
[54] Dessouroux A , Akwa Y, Baulieu E E. J . Steroid. Biochem.Mol . Biol . , 2008 , 109 : 81 —89
[55] Lee K, Lee J H , Boovanahalli S K, et al . J . Med. Chem. ,2007 , 50 (7) : 1675 —1684
[56] Boovanahalli S K, Jin X, Jin Y, et al . Bioorg. Med. Chem.Lett . , 2007 , 17 : 6305 —6310
[57] Jang M, Cai L , Udeani GO , et al . Science , 1997 , 275 : 218 —220
[58] Cao Z, Fang J , Xia C , et al . Clin. Cancer Res. , 2004 , 10 :5253 —5263
[59] Park S Y, Jeong K J , Lee J , et al . Cancer Lett . , 2007 , 258 :63 —69
[60] Kueck A , Opipari A W, Griffith K A , et al . Gynecol . Oncol . ,2007 , 107 : 450 —457
[61] Choi I Y, Kim S J , Jeong H J , et al . Mol . Cell Biochem. ,2007 , 305 : 153 —161
[62] 叶德举(Ye D J ) , 罗小民(Luo XM) , 沈建华(Shen J H) 等.化学进展(Progress in Chemistry) , 2007 , 19 (12) : 1939 —1946
[63] Kondo K, Klco J , Nakamura E , et al . Cancer Cell , 2002 , 1 :237 —246
[64] Carmeliet P , Dor Y, Herbert J M, et al . Nature , 1998 , 394 :485 —490
[65] Marignol L , Coffey M, Lawler M, et al . Cancer Treat . Rev. ,2008 : 34 : 313 —327
[1] Dang Zhang, Xi Wang, Lei Wang. Biomedical Applications of Enzyme-Powered Micro/Nanomotors [J]. Progress in Chemistry, 2022, 34(9): 2035-2050.
[2] Xiaodong Jing, Ying Sun, Bing Yu, Youqing Shen, Hao Hu, Hailin Cong. Rational Design of Tumor Microenvironment Responsive Drug Delivery Systems [J]. Progress in Chemistry, 2021, 33(6): 926-941.
[3] Jiajia Wang, Huiying Wu, Renfeng Dong, Yuepeng Cai. Micro/Nanomotors on the Way to Intelligent Cancer Diagnosis, Delivery and Therapy [J]. Progress in Chemistry, 2021, 33(5): 883-894.
[4] Yunxue Wu, Hengyi Zhang, Yu Liu. Application of Azobenzene Derivative Probes in Hypoxia Cell Imaging [J]. Progress in Chemistry, 2021, 33(3): 331-340.
[5] Xinyu Wang, Fuping Zhao, Ru Zhang, Ziru Sun, Shengnan Liu, Qingzhi Gao. Development of Hypoxia Inducible Factor-1 Small Molecule Inhibitors as Antitumor Agents [J]. Progress in Chemistry, 2021, 33(12): 2259-2269.
[6] Shan Guo, Xiang Zhou. Detection of Circulating Tumor Cell in Vivo:Technology and Application [J]. Progress in Chemistry, 2021, 33(1): 1-12.
[7] Ziru Sun, Shengnan Liu, Qingzhi Gao. Development of Anticancer Drugs Targeting Glucose Transporters(GLUTs) [J]. Progress in Chemistry, 2020, 32(12): 1869-1878.
[8] Xinyi Lai, Zhiyong Wang, Yongtai Zheng, Yongming Chen. Nanoscale Metal Organic Frameworks for Drug Delivery [J]. Progress in Chemistry, 2019, 31(6): 783-790.
[9] Bingde Zheng, Yuanyuan Zhao, Hongcai Li, Biyuan Zheng, Meirong Ke, Jiandong Huang*. Activatable Photodynamic Anticancer Photosensitizers [J]. Progress in Chemistry, 2018, 30(9): 1403-1414.
[10] Xiang Li, Jiayuan Shi, Shuang Qiu, Mingfang Wang, Changlin Liu*. SOD1 Inhibition Regulates the ROS Signaling Transduction [J]. Progress in Chemistry, 2018, 30(10): 1475-1486.
[11] Liang He, Caiping Tan, Qian Cao, Zongwan Mao. Application of Phosphorescent Cyclometalated Iridium(Ⅲ) Complexes in Cancer Treatment [J]. Progress in Chemistry, 2018, 30(10): 1548-1556.
[12] Juan Shen, Yang Zhu, Hongdong Shi, Yangzhong Liu. Multifunctional Nanodrug Delivery Systems for Platinum-Based Anticancer Drugs [J]. Progress in Chemistry, 2018, 30(10): 1557-1572.
[13] Gong Zhaocui, Yin Chao, Zhao Hui, Lu Xiaomei, Fan Quli, Huang Wei. Light-Controlled Nanocarriers for Drug Release [J]. Progress in Chemistry, 2016, 28(9): 1387-1396.
[14] Jiang Ge, Luo Feng, Xu Yaozhong, Zhang Xiaohui. UVA Assisted 4-Thiothymidine for Cancer Treatment [J]. Progress in Chemistry, 2016, 28(8): 1224-1237.
[15] Zheng Xiaohui, Xia Lixin, Mao Zongwan. The New Anticancer Platinum Complex Designed on the Basis of Nucleic Acid [J]. Progress in Chemistry, 2016, 28(7): 1029-1038.